Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production
Natalia Fintelman‐Rodrigues(Fundação Oswaldo Cruz), Thiago Moreno L. Souza(National Institute of Science and Technology), Aline da Rocha Matos(Fundação Oswaldo Cruz), Marilda Mendonça Siqueira(Fundação Oswaldo Cruz), Carolina Q. Sacramento(National Institute of Science and Technology), Milene Dias Miranda(Fundação Oswaldo Cruz), Carlyle Ribeiro Lima, Franklin Souza‐Silva(Universidade Iguaçu), Patrı́cia T. Bozza(Fundação Oswaldo Cruz), Carlos Roberto Alves(Fundação Oswaldo Cruz), Nicolas Carels(Faculdades Oswaldo Cruz), Fernando A. Bozza(D’Or Institute for Research and Education), Suelen da Silva Gomes Dias(Fundação Oswaldo Cruz), Jairo R. Temerozo(Fundação Oswaldo Cruz), Mayara Mattos(Fundação Oswaldo Cruz), Vinícius Cardoso Soares(Universidade Federal do Rio de Janeiro), André C. Ferreira(Fernando Pessoa University), Caroline S. de Freitas(Fundação Oswaldo Cruz)
Cited by 69
Related Papers
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
|Cell|2022|1k
Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19
|Blood|2020|776
Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis
|Critical Care|2007|744